PDCD1 and glioblastoma: It has been shown that the activation of the MAPK/ERK signaling pathway can be associated with response to PD-1 inhibitors in patients with recurrent GBM and that p-ERK, which is considered a marker of this pathway activation, can be a biomarker that predicts survival in these patients [246].